^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    WT2725

    i
    Other names: WT-2725, Wilms tumor 1 (WT1) peptide cancer vaccine, WT 2725, WT2725
    Associations

    News

    Trials
    Company:
    Sumitomo Pharma
    Drug class:
    Immunostimulant, Wilms tumor 1 inhibitor
    Related drugs:
    Associations

    News

    Trials
    over2years
    A phase I study of the WT2725 dosing emulsion in patients with advanced malignancies. (PubMed, Sci Rep)
    WT2725 dosing emulsion was well tolerated. Preliminary tumor response and biological marker data suggest that WT2725 dosing emulsion may exert antitumor activity in malignancies known to overexpress the WT1 protein, particularly glioblastoma, and provide a rationale for future clinical development.Trial registration: NCT01621542.
    Clinical • P1 data • Clinical Trial,Phase I • Journal
    |
    WT1 (WT1 Transcription Factor)
    |
    WT1 overexpression
    |
    WT2725